臺灣博碩士論文加值系統

非酒精性脂肪肝疾病是指非因飲酒過量而導致肝臟有超過5%的脂肪堆積在肝細胞中的慢性肝臟疾病，近年來國內成人患有非酒精性脂肪肝疾病的盛行率高達26-34%。而非酒精性脂肪肝疾病一般認為是不需要積極治療，但需要避免進一步演變成非酒精性脂肪肝炎。許多研究更顯示，非酒精性脂肪肝炎的患者有相當的比例會發展成肝纖維化、肝硬化甚至是肝癌。目前研究指出，給小鼠腹腔注射二乙基亞硝胺及餵食高油脂的食物，會藉由增加肝臟TNF-alpha與IL-6的表現造成肝臟發炎與纖維化的形成。本實驗的研究目的是想了解在我們研發的中草藥複方B，在給小鼠腹腔注射二乙基亞硝胺及餵食高油脂高膽固醇飲食造成的非酒精性脂肪肝炎與肝臟纖維化的動物模式中，是否具有預防的功效。
我們先前的研究發現，小鼠在高油脂高膽固醇飲食之下給予中草藥複方B具有預防脂肪肝的功效。而我們進一步地在這次動物實驗中評估複方B的抗肝臟發炎和纖維化的潛力。動物實驗使用3週大C57BL/6公鼠進行實驗，將之分為四組，控制組餵食正常飼料以及灌食滅菌水，另外三組實驗組皆餵食高油脂高膽固醇飼料及10%果糖水以及每2週腹腔注射一劑二乙基亞硝胺，其中B( 0 mg/kg)組每天灌食滅菌水，B(450mg/kg) and B(900mg/kg)組每天分別灌食相當於每公斤體重給予450與900毫克的複方B藥材乾重。飼養6週與12週實驗後，結果顯示灌食複方B不僅可顯著減少肝臟三酸甘油酯及總膽固醇含量，也能顯著降低血漿中AST和ALT活性。肝臟組織切片亦發現具有明顯改善脂肪油滴堆積、發炎反應及纖維化之情形。以RT-Q-PCR分析發炎細胞激素與免疫細胞入侵及肝纖維化指標之基因表現，結果顯示灌食複方B可減少TNF-alpha, IL-6, MCP-1, F4/80, AFP, alpha-SMA, TGF-beta 1以及Collagen type I的 mRNA 量。以免疫組織染色分析的結果也顯示灌食複方B可降低CD68及alpha-SMA的蛋白質表現。由這些結果顯示複方B在此動物模式下具有預防非酒精性脂肪肝、肝臟發炎與纖維化之效用。
我們也探討組合成B配方的3種中草藥單方萃取物(代號A14、A28及A50號)，是否對於油酸(Oleic acid, OA)所誘導的細胞三酸甘油酯以及發炎細胞激素基因表現存有抑制的功效。將HepG2 細胞同時處理油酸以及單方中草藥萃取物24小時，測量細胞內三酸甘油酯含量以及TNF-alpha與IL-6的mRNA表現，結果顯示A28與A50號單方中草藥萃取物可以降低油酸所增加的細胞三酸甘油酯以及發炎細胞激素的基因表現。
由動物實驗結果發現，B複方具有預防二乙基亞硝胺及餵食高油脂高膽固醇飼料造成的非酒精性脂肪肝、脂肪肝炎與肝臟纖維化之功效。後續的研究可以找出B複方的有效成分及作用的分子機制。

Nonalcoholic fatty liver disease (NAFLD) is a disease which is defined as more than 5% fat accumulation in hepatocytes of people who consumed limited amount of alcohol. The prevalence of NAFLD in Taiwan is about 26-34%. Non-alcoholic steatohepatitis (NASH) is more progressive form of NAFLD. Many studies suggest that NASH patients have a higher risk for liver fibrosis progression, the most common risk factor for cirrhosis and hepatocellular carcinoma. A recent study demonstrated that diethylnitrosamine (DEN) and high fat diet promote liver inflammation and tumorigenesis by enhancing TNF-alpha and IL-6 expression. Our previous study identified a CHM mixture-Mix B that prevents high fat/high cholesterol diet-induced NAFLD. The aim of this study is to test if the Chinese herbal medicines (CHM) mixture-Mix B can be used to prevent DEN and high fat/high cholesterol diet induced NASH and liver fibrosis.
In this study, we evaluate if Mix B has anti-inflammatory and anti-fibrogenic potential in vivo. Three-week old male C57BL/6 mice were used in this study, they were divided into four groups. The control group was fed with chow diet and given distilled water by gavage. The three experimental groups were fed high fat/high cholesterol diet, 10% fructose water and intraperitoneally injected with DEN every 2 weeks, and the B( 0 mg/kg) was gavaged with normal saline, B(450mg/kg) and B(900mg/kg) were gavaged with 450 mg/kg and 900mg/kg Mix B, respectively, daily for 12 weeks. After 6 and 12 weeks of treatment, Mix B not only significantly lowered liver triacylglycerol (TG) and cholesterol but also significantly reduced plasma AST and ALT activities. Histological analyses showed that Mix B improved liver steatosis, inflammation and fibrosis significantly. Mix B also decreased mRNA levels of pro-inflammatory cytokines, macrophage infiltration and fibrosis marker genes, such as TNF-alpha,IL-6, MCP-1, F4/80, AFP, alpha-SMA, TGF-beta 1 and Collagen type I. Immunohistochemistry analyses showed that mice fed with Mix B expressed less CD68 and alpha-SMA in the liver. The results suggest that Mix B could inhibit liver fat accumulation, inflammation and fibrosis.
We further tested if the three components of Mix B ( code number: A14、A28、A50) can reduce oleic acid-induced expression of proinflammatory cytokines in HepG2. Cells were treated with the CHMs and oleic acid for 24h, and cellular TG and mRNA levels of TNF-alpha and IL-6 were determined. Results show that the CHMs (code number: A28 and A50) prevented oleic acid-induced increase of cellular TG and expression of TNF-alpha and IL-6 mRNAs.
Taken together, our results show that Mix B is effective in prevention of DEN and high fat/high cholesterol diet-induced NASH and liver fibrosis. Further studies on the identification and isolation of the functional component(s) in Mix B, and the underline molecular mechanisms are deserved.

摘要 iv
Abstract vi
縮寫對照表 viii
第一章、緒論 1
第一節、文獻回顧 2
第二節、研究動機與實驗目的 10
第二章、材料與方法 12
第一節、實驗材料 13
第二節、細胞實驗 14
第三節、動物實驗 19
第四節、統計分析 25
第三章、實驗結果 26
第一節、C57BL/6雄性小鼠動物實驗 27
第二節、HepG2細胞實驗 32
第四章、討論 34
第一節、動物實驗 35
第二節、細胞實驗 42
第三節、總結 43
第五章、圖表 45
參考文獻： 69
附錄: 藥品配製 80

Almeida, I.T.d., Cortez-Pinto, H., Rodrigues, G., Rodrigues, D., and Camilo, M.E. (2002). Plasma total and free fatty acids composition in human non-alcoholic steatohepatitis. Clinical Nutrition 21, 219-223.
Babali, A., Cakal, E., Purnak, T., Biyikoglu, I., Cakal, B., Yuksel, O., and Koklu, S. (2009). Serum alpha-fetoprotein levels in liver steatosis. Hepatol Int 3, 551-555.
Bataller, R., and Brenner, D.A. (2005). Liver fibrosis. Journal of Clinical Investigation 115, 209-218.
Berg, T.K.v.d., and Kraal, G. (2005). A function for the macrophage F4/80 molecule in tolerance induction. Trends in Immunology 26, 506-509.
Border, W.A., and Noble, N.A. (1994). Transforming growth factor b in tissue fibrosis. The new England journal of medicine 331, 1286-1292.
Breitkopf, K., Haas, S., Wiercinska, E., Singer, M.V., and Dooley, S. (2005). Anti-TGF-beta- Strategies for the Treatment of Chronic Liver Disease. Alcoholism: Clinical & Experimental Research 29, 121-131.
Browning, J.D., and Horton, J.D. (2004). Molecular mediators of hepatic steatosis and liver injury. Journal of Clinical Investigation 114, 147-152.
Carpino, G., Morini, S., Ginannicorradini, S., Franchitto, A., Merli, M., Siciliano, M., Gentili, F., Onettimuda, A., Berloco, P., and Rossi, M. (2005). Alpha-SMA expression in hepatic stellate cells and quantitative analysis of hepatic fibrosis in cirrhosis and in recurrent chronic hepatitis after liver transplantation. Digestive and Liver Disease 37, 349-356.
Chakraborty, T., Pandey, N., Chatterjee, A., Ghosh, B., Rana, B., and Chatterjee, M. (2006). Molecular basis of anticlastogenic potential of vanadium in vivo during the early stages of diethylnitrosamine-induced hepatocarcinogenesis in rats. Mutat Res 609, 117-128.
Chitturi, S., Farrell, G.C., Hashimoto, E., Saibara, T., Lau, G.K.K., and Sollano, J.D. (2007). Non-alcoholic fatty liver disease in the Asia-Pacific region: Definitions and overview of proposed guidelines. Journal of Gastroenterology and Hepatology 22, 778-787.
Chuang, S.E., Kuo, M.L., Hsu, C.H., Chen, C.R., Lin, J.K., Lai, G.M., Hsieh, C.Y., and Cheng, A.L. (2000). Curcumin-containing diet inhibits diethylnitrosamine-induced murine hepatocarcinogenesis. Carcinogenesis 21, 331-335.
Cl´ement, S., Juge-Aubry, C., Sgroi, A., Conzelmann, S.e., Pazienza, V., Pittet-Cuenod, B., Meier, C.A., and Negro, F. (2008). Monocyte Chemoattractant Protein-1 Secreted by Adipose Tissue Induces Direct Lipid Accumulation in Hepatocytes. Hepatology 48, 799-807.
Cui, W., Chen, S.L., and Hu, K.-Q. (2010). Quantification and mechanisms of oleic acid-induced steatosis in HepG2 cells. Am J Transl Res 2, 95-104.
Day, C.P., and James, O.F. (1998). Steatohepatitis: a tale of two "hits"? Gastroenterology 114, 842-845.
Donnelly, K.L., Smith, C.I., Schwarzenberg, S.J., Jessurun, J., Boldt, M.D., and Parks, E.J. (2005). Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 115, 1343-1351
Esterbauer, H., Schaur, R.J., and Zollner, H. (1991). Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radical Biology and Medicine 11, 81-128.
Fausto, N., and Campbell, J. (2010). Mouse Models of Hepatocellular Carcinoma. Seminars in Liver Disease 30, 87-98.
Friedman, S.L. (2000). Molecular Regulation of Hepatic Fibrosis, an Integrated Cellular Response to Tissue Injury. The journal of biological chemistry 275, 2247-2250.
Hasegawa, T., Yoneda, M., Nakamura, K., Makino, I., and Terano, A. (2001). Plasma transforming growth factor-beta1 level and efficacy of alpha-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study. Aliment Pharmacol Ther 15, 1667-1672.
Hedler, L., and Marquardt, P. (1968). Occurrence of Diethylnitrosamine in Some Samples of Food. Food and Cosmetics Toxicology 6, 341-348.
Heindryckx, F., Colle, I., and Van Vlierberghe, H. (2009). Experimental mouse models for hepatocellular carcinoma research. International Journal of Experimental Pathology 90, 367-386.
Hensley, K., Kotake, Y., Sang, H., N.Pye, Q., L.Wallis, G., M.Kolker, L., Tabatabaie, T., A.Stewart, C., Konishi, Y., Nakae, D., Floyd, R.A. (2000). Dietary choline restriction causes complex I dysfunction and increased H2O2 generation in liver mitochondria. Carcinogenesis 21, 983-989.
Hirosumi, J., Tuncman, G., Chang, L., Gorgun, C.Z., Uysal, K.T., Maeda, K., Karin, M., and Hotamisligil, G.S. (2002). A central role for JNK in obesity and insulin resistance. Nature 420, 333-336.
Hu, K.-Q., Kyulo, N.L., Lim, N., Elhazin, B., Hillebrand, D.J., and Bock, T. (2004). Clinical Significance of Elevated Alpha-Fetoprotein (AFP) in Patients with Chronic Hepatitis C, but not Hepatocellular Carcinoma. American Journal of Gastroenterology 99, 860-865.
Kanda, H. (2006). MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. Journal of Clinical Investigation 116, 1494-1505.
Karin, M. (2008). The IκB kinase – a bridge between inflammation and cancer. Cell Research 18, 334-342.
Kim, J.J., Lee, S.B., Park, J.K., and Yoo, Y.D. (2010). TNF-α-induced ROS production triggering apoptosis is directly linked to Romo1 and Bcl-XL. Cell Death and Differentiation 17, 1420-1434.
Kinoshita, M., Uchida, T., Sato, A., Nakashima, M., Nakashima, H., Shono, S., Habu, Y., Miyazaki, H., Hiroi, S., and Seki, S. (2010). Characterization of two F4/80-positive Kupffer cell subsets by their function and phenotype in mice. Journal of Hepatology 53, 903-910.
Kisseleva, T., and Brenner, D.A. (2006). Hepatic stellate cells and the reversal of fibrosis. Journal of Gastroenterology and Hepatology 21, 84-87.
Kugelmas, M., Hill, D.B., Vivian, B., Marsano, L., and McClain, C.J. (2003). Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E. Hepatology 38, 413-419.
Lee, K.S., Buck, M., Houglum, K., and Chojkier, M. (1995). Activation of Hepatic Stellate Cells by TGF-a and Collagen Type I Is Mediated by Oxidative Stress Through c-myb Expression. The Journal of Clinical Investigation 96, 2461-2468.
Leonarduzzi, G., Scavazza, A., Biasi, F., Chiarpotfo, E., Camandola, S., Vogl, S., Dargel, R., and Poli, G. (1997). The lipid peroxidation end product 4-hydroxy-2,3-nonenal up-regulates transforming growth factor beta1 expression in the macrophage lineage: a link between oxidative mjury and fibroscierosis. The Journal of the Federation of American Societies for Experimental Biology 11, 851-857.
Li, T., Owsley, E., Matozel, M., Hsu, P., Novak, C.M., and Chiang, J.Y.L. (2010). Transgenic expression of cholesterol 7α-hydroxylase in the liver prevents high-fat diet-induced obesity and insulin resistance in mice. Hepatology 52, 678-690.
Lin, S.C., Lin, C.C., Lu, F.J., Lin, Y.H., and Chen, C.H. (1996). Protective and therapeutic effects of huanglian-jie-du-tang on hepatotoxin-induced liver injuries. Am J Chin Med 24, 219-229.
Lutchman, G., Promrat, K., Kleiner, D.E., Heller, T., Ghany, M.G., Yanovski, J.A., Liang, T.J., and Hoofnagle, J.H. (2006). Changes in serum adipokine levels during pioglitazone treatment for nonalcoholic steatohepatitis: relationship to histological improvement. Clin Gastroenterol Hepatol 4, 1048-1052.
Lutticken, C., Wegenka, U.M., Yuan, J., Buschmann, J., Schindler, C., Ziemiecki, A., Harpur, A.G., Wilks, A.F., Yasukawa, K., Taga, T., et al. (1994). Association of Transcription Factor APRF and Protein Kinase Jakl with the Interleukin-6 Signal Transducer gp130. Science 263, 89-92.
Maher, J.J., and McGuire, R.F. (1990). Extracellular Matrix Gene Expression Increases Preferentially in Rat Lipocytes and Sinusoidal Endothelial Cells during Hepatic Fibrosis In Vivo. The Journal of Clinical Investigation 86, 1641-1648.
Malhi, H., and Gores, G. (2008). Molecular Mechanisms of Lipotoxicity in Nonalcoholic Fatty Liver Disease. Seminars in Liver Disease 28, 360-369.
Marí, M., Caballero, F., Colell, A., Morales, A., Caballeria, J., Fernandez, A., Enrich, C., Fernandez-Checa, J.C., and García-Ruiz, C. (2006). Mitochondrial free cholesterol loading sensitizes to TNF-a and Fas-mediated steatohepatitis. Cell Metabolism 4, 185-198.
Min, L., He, B., and Hui, L. (2011). Mitogen-activated protein kinases in hepatocellular carcinoma development. Seminars in Cancer Biology 21, 10-20.
Mutungi, G., Torres-Gonzalez, M., McGrane, M.M., Volek, J.S., and Fernandez, M.L. (2007). Carbohydrate restriction and dietary cholesterol modulate the expression of HMG-CoA reductase and the LDL receptor in mononuclear cells from adult men. Lipids Health Dis 6, 1-4.
Nan, J.X., Park, E.J., Kang, H.C., Park, P.H., Kim, J.Y., and Sohn, D.H. (2001). Anti-fibrotic effects of a hot-water extract from Salvia miltiorrhiza roots on liver fibrosis induced by biliary obstruction in rats. J Pharm Pharmacol 53, 197-204.
Newell, P., Villanueva, A., Friedman, S.L., Koike, K., and Llovet, J.M. (2008). Experimental models of hepatocellular carcinoma. Journal of Hepatology 48, 858-879.
Neuschwander-Tetri, B.A., Brunt, E.M., Wehmeier, K.R., Oliver, D., and Bacon, B.R. (2003). Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology 38, 1008-1017.
Nouchi, T., Tanaka, Y., Tsukada, T., Sato, C., and Marumo, F. (1991). Appearance of a-smooth-muscle-actin-positive cells in hepatic fibrosis. Liver 11, 100-105.
Park, E.J., Lee, J.H., Yu, G.-Y., He, G., Ali, S.R., Holzer, R.G., Österreicher, C.H., Takahashi, H., and Karin, M. (2010). Dietary and Genetic Obesity Promote Liver Inflammation and Tumorigenesis by Enhancing IL-6 and TNF Expression. Cell 140, 197-208.
Pinzani, M. (1995). Hepatic stellate (ITO) celk expanding roles for a liver-specific pericyte. Journol of Hepatology 22, 700-706.
Pradeep, K., Mohan, C.V., Gobianand, K., and Karthikeyan, S. (2007). Silymarin modulates the oxidant-antioxidant imbalance during diethylnitrosamine induced oxidative stress in rats. Eur J Pharmacol 560, 110-116.
Puri, P., Baillie, R.A., Wiest, M.M., Mirshahi, F., Choudhury, J., Cheung, O., Sargeant, C., Contos, M.J., and Sanyal, A.J. (2007). A Lipidomic Analysis of Nonalcoholic Fatty Liver Disease. Hepatology 46 1081-1090.
Ratziu, V., and Poynard, T. (2006). Assessing the outcome of nonalcoholic steatohepatitis? It''s time to get serious. Hepatology 44, 802-805.
Reddy, J.K., and Rao, M.S. (2006). Lipid metabolism and liver inflammation. II. Fatty liver disease and fatty acid oxidation. Am J Physiol Gastrointest Liver Physiol 290, 852-858.
Sanal, M.G. (2008). The blind men ''see'' the elephant-the many faces of fatty liver disease. World J Gastroenterol 14, 831-844.
Seki, S., Kitada, T., Yamada, T., Sakaguchi, H., Nakatani, K., and Wakasa, K. (2002). In situ detection of lipid peroxidation and oxidative DNA damage in non-alcoholic fatty liver diseases. Journal of Hepatology 37, 56-62.
Shimizu, I. (2000). Sho-saiko-to: Japanese herbal medicine for protection against hepatic fibrosis and carcinoma. Journal of Gastroenterology and Hepatology 15, 84-90.
Spruss, A., Kanuri, G., Wagnerberger, S., Haub, S., Bischoff, S.C., and Bergheim, I. (2009). Toll-Like Receptor 4 Is Involved in the Development of Fructose-Induced Hepatic Steatosis in Mice. Hepatology 50, 1094-1104.
Streetz, K.L., Luedde, T., Manns, M.P., and Trautwein, C. (2000). Interleukin 6 and liver regeneration. Gut 47, 309-312.
Tetri, L.H. (2008). Severe NAFLD with hepatic necroinflammatory changes in mice fed trans fats and a high-fructose corn syrup equivalent. Am J Physiol Gastrointest Liver Physiol 295, 987-995.
Trauner, M., Arrese, M., and Wagner, M. (2010). Fatty liver and lipotoxicity. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids 1801, 299-310.
Vergnes, L. (2003). Cholesterol and Cholate Components of an Atherogenic Diet Induce Distinct Stages of Hepatic Inflammatory Gene Expression. Journal of Biological Chemistry 278, 42774-42784.
Wang, Y., Ausman, L.M., Greenberg, A.S., Russell, R.M., and Wang, X.-D. (2009). Nonalcoholic steatohepatitis induced by a high-fat diet promotes diethylnitrosamine-initiated early hepatocarcinogenesis in rats. International Journal of Cancer 124, 540-546.
Wanless, I.R., and Lentz, J.S. (1990). Fatty Liver Hepatitis (Steatohepatitis) and Obesity: An Autopsy Study with Analysis of Risk Factors. Hepatology 12, 1106-1110.
Wouters, K., van Gorp, P.J., Bieghs, V., Gijbels, M.J., Duimel, H., Lütjohann, D., Kerksiek, A., van Kruchten, R., Maeda, N., Staels, B., Van Bilsen, M., Shiri-Sverdlov, R., Hofker, M. H. (2008). Dietary cholesterol, rather than liver steatosis, leads to hepatic inflammation in hyperlipidemic mouse models of nonalcoholic steatohepatitis. Hepatology 48, 474-486.
Yamada, K., Yamamiya, I., and Utsumi, H. (2006). In vivo detection of free radicals induced by diethylnitrosamine in rat liver tissue. Free Radic Biol Med 40, 2040-2046.
Yamauchi, T., Kamon, J., Waki, H., Imai, Y., Shimozawa, N., Hioki, K., Uchida, S., Ito, Y., Takakuwa, K., Matsui, J., Takata, M., Eto, K., Terauchi, Y., Komeda, K., Tsunoda, M., Murakami, K., Ohnishi, Y., Naitoh, T., Yamamura, K., Ueyama, Y., Froguel, P., Kimura, S., Nagai, R., Kadowaki, T. (2003). Globular Adiponectin Protected ob/ob Mice from Diabetes and ApoE-deficient Mice from Atherosclerosis. Journal of Biological Chemistry 278, 2461-2468.
Zheng, J.-F., and Liang, L.-J. (2008). Intra-portal transplantation of bone marrow stromal cells ameliorates liver fibrosis in mice. Hepatobiliary and Pancreatic Diseases International 7, 264-270.
劉娟秀 (1992) 膽固醇性脂肪肝機轉之研究。國立台灣大學醫學院生化學研究所博士論文。
賴昱昇 (2009) 具有治療非酒精性脂肪肝之中草藥之篩選。國立台灣大學醫學院生化學研究所碩士論文。
郝立智與柴國樑 (2004) 漫談脂肪肝。台灣醫學雜誌，第47卷第1期。
侯丞 (2009) 我有脂肪肝---怎麼辦？台灣肝臟學術文教基金會刊第38期。